Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Liabilities: 2012-2025

Historic Other Non-Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 4 years, with Sep 2025 value amounting to $90,000.

  • Agios Pharmaceuticals' Other Non-Current Liabilities fell 92.21% to $90,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $90,000, marking a year-over-year decrease of 92.21%. This contributed to the annual value of $880,000 for FY2024, which is 23.88% down from last year.
  • Agios Pharmaceuticals' Other Non-Current Liabilities amounted to $90,000 in Q3 2025, which was down 10.89% from $101,000 recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $3.3 million for Q4 2022, and its period low was $90,000 during Q3 2025.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $1.2 million (2024), whereas its average is $927,273.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first grew by 9.57% in 2023, then plummeted by 92.21% in 2025.
  • Agios Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $3.3 million in 2022, then crashed by 64.75% to $1.2 million in 2023, then fell by 23.88% to $880,000 in 2024, then plummeted by 92.21% to $90,000 in 2025.
  • Its Other Non-Current Liabilities stands at $90,000 for Q3 2025, versus $101,000 for Q2 2025 and $880,000 for Q1 2025.